Telomerase-Specific Oncolytic Virotherapy for Human Cancer with the hTERT Promoter

E-ISSN： 1873-5576|7|2|191-201

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.7, Iss.2, 2007-03, pp. : 191-201

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 9, 2012-07 ,pp. : 1809-1816

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation

Current Cancer Drug Targets, Vol. 18, Iss. 1, 2017-12 ,pp. : 97-106

Bentham Science Publishers

Access to resources Recommend Favorite

Oncolytic Virotherapy for Breast Cancer Treatment

Current Gene Therapy, Vol. 18, Iss. 4, 2018-08 ,pp. : 192-205

Bentham Science Publishers

Access to resources Recommend Favorite

Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

By Ouchi Masaaki Kawamura Hitoshi Urata Yasuo Fujiwara Toshiyoshi

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 241-245

Springer Publishing Company

Access to resources Recommend Favorite

Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer

Current Pharmaceutical Design, Vol. 20, Iss. 42, 2014-12 ,pp. : 6513-6521

Bentham Science Publishers

Access to resources Recommend Favorite